Login to Your Account



Isis Inks Potential $1.5B GSK Option Deal for Anti-RNA Drugs

By Jennifer Boggs


Thursday, April 1, 2010
Though much-anticipated Phase III mipomersen data aren't expected until later this year, Isis Pharmaceuticals Inc. gave investors a nice surprise with news of a potential $1.5 billion RNA drug discovery alliance with GlaxoSmithKline plc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription